Skip to main content

TaiRx, Inc. (6580.TWO)

Taipei Exchange (Taiwan) Healthcare BiotechnologyView data quality →
37.3Poor

ValueMarkers Composite Index

Top 3%#43,570 of 44,714

DCF data not available

Piotroski
4/9
Neutral
Beneish
-1.78
Investigate
Altman
24.36
Safe
DCF Value
-
N/A
ROIC
-40.3%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

TaiRx, Inc. (6580.TWO) — VMCI valuation read

Composite valuation read on 6580.TWO: VMCI 37/100 against a Healthcare sector median of 50. The 13-point below-median print is the headline number for TaiRx, Inc., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for 6580.TWO: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on 6580.TWO: 6580.TWO trades at 21.0x earnings, 17% above the Healthcare median of 18.0x; ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp; net debt to EBITDA of 1.7x is the rate-sensitivity line to watch. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

6580.TWO rose 2.3% over the trailing 7 days, with a +2.8% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 6580.TWO’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.